Available commercially as ibs-smart, the test could provide physicians with the most conclusive data currently attainable for ruling in IBS.
Primarily applicable to patients with a diarrheal component to their symptoms, the test could serve up to two-thirds of the 45m Americans suffering from IBS.
After over a decade of uncovering the pathophysiology of post-infectious IBS, researchers at Cedars-Sinai validated the antibodies anti-CdtB and anti-vinculin as highly specific biomarkers measurable in blood.
This innovative blood test offered patients the first-ever opportunity to receive a diagnosis of IBS by ruling in the disease, rather than by ruling out other diseases.
Scientists at the Medically Associated Science and Technology program at Cedars-Sinai, in collaboration with Gemelli Biotech, developed a proprietary epitope optimization process that was instrumental to improving the test for its second-generation launch as ibs-smart.
Cedars-Sinai has entered into an exclusive license agreement with Gemelli Biotech for several patent applications covering the blood test technology.
At Digestive Disease Week (DDW 2019) in San Diego, the MAST team reported the results of their validation study.
The second-generation blood test is >90% specific in distinguishing patients with IBS from patients with Inflammatory Bowel Disease using each marker.
When combined, the post-test probability of IBS is >98%. That means that for the first time, a near certain diagnosis of IBS can be made if both biomarkers are elevated.
Gemelli Biotech is determined to bring ibs-smart to physicians worldwide. Physicians in the US can order the test for patients via a kit-based system.
The company helps interested patients find local specialists and blood draw labs. Samples are tested in a CLIA-certified lab in Irvine, California. The test is covered at least in part by most insurance providers.
Dr. Mark Pimentel, Executive director of the MAST programme, as well as a practicing gastroenterologist and co-founder of Gemelli Biotech, believes the greater diagnostic accuracy is meaningful to patients and doctors alike.
ibs-smart is the second-generation blood test for Irritable Bowel Syndrome and offers an advancement in the specificity and accuracy of data available to help doctors diagnose Diarrhea Predominant and Mixed-Type IBS (IBS-D and IBS-M).
Gemelli Biotech is a specialty biotechnology company that strives to achieve a thriving global family of healthy individuals by unlocking the potential of the microbiome. Gemelli's mission is to support the discovery of novel diagnostics and therapeutics for the human microbiome by bringing biotechnology innovations to market in a fiscally responsible and socially conscious way.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial